Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that
includes haploidentical donor NK cells followed by the infusion of selectively T-cell
depleted progenitor cell grafts work in treating younger patients with hematologic
malignancies that have returned after or did not respond to treatment with a prior
transplant. Giving chemotherapy and natural killer cells before a donor progenitor cell
transplant may help stop the growth of cells in the bone marrow, including normal
blood-forming cells (progenitor cells) and cancer cells. It may also stop the patient's
immune system from rejecting the donor's cells. When the healthy progenitor cells from a
related donor are infused into the patient they make red blood cells, white blood cells, and
platelets. Sometimes the transplanted cells from a donor can make an immune response against
the body's normal cells (called graft-versus-host disease). Removing specific T cells from
the donor cells before the transplant may prevent this.